Basic Information
CellCentric is a UK-based anticancer drug developer. Its candidate drug, CCS1477, is an orally available inhibitor of histone acetyltransferases p300 and CBP that targets the conserved bromodomain of these two proteins and is applicable for the treatment of prostate cancer.
CellCentric Limited
Cambridge,England,United Kingdom
less than 15 people
January 01, 2003
info@cellcentric.com
Enterprise Profile
Industrial Sector
Technology
Concept
Application Scenarios